Drugs related to monoamine oxidase activity

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 69, Issue , 2016, Pages 112-124

  Fišar, Zdeněk ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Hybrid drug; Mental disorder; Monoamine oxidase; Monoamine oxidase inhibitor; Neuroprotection

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AZURE B; CHOLINESTERASE INHIBITOR; CLORGYLINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EPROBEMIDE; IPRONIAZID; ISOCARBOXAZID; LADOSTIGIL; LAZABEMIDE; LINEZOLID; MEMOQUIN; MITOCHONDRIAL ENZYME; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PHENELZINE; PROPARGYLAMINE DERIVATIVE; RALFINAMIDE; RASAGILINE; SAFINAMIDE; SELEGILINE; SEROTONIN; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONISAMIDE;

AGGRESSION; ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; BIPOLAR DISORDER; DEGENERATIVE DISEASE; DEPRESSION; DRUG DEPENDENCE; DRUG MECHANISM; DRUG TARGETING; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SUBSTRATE COMPLEX; HUMAN; MENTAL DISEASE; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; SCHIZOPHRENIA; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; MENTAL DISORDERS; METABOLISM; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; SYNAPTIC TRANSMISSION; SYNTHESIS;

ANIMALS; HUMANS; MENTAL DISORDERS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEURODEGENERATIVE DISEASES; SYNAPTIC TRANSMISSION;

EID: 84959924226     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2016.02.012     Document Type: Article

References (221)

1. aan het Rot M., Mathew S.J., Charney D.S. Neurobiological mechanisms in major depressive disorder. CMAJ 2009, 180(3):305-313.
2. Allain H., Lieury A., Brunet-Bourgin F., Mirabaud C., Trebon P., Le Coz F., Gandon J.M. Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology 1992, 106(SUPPL.):S56-S61.
3. Anand A., Barkay G., Dzemidzic M., Albrecht D., Karne H., Zheng Q.H., Hutchins G.D., Normandin M.D., Yoder K.K. Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord. 2011, 13(4):406-413.
4. Andalib S., Vafaee M.S., Gjedde A. Parkinson's disease and mitochondrial gene variations: a review. J. Neurol. Sci. 2014, 346(1-2):11-19.
5. Andreeva N.I., Golovina S.M., Faermark M.F., Shvarts GIa, Mashkovskiĭ M.D. The comparative influence of pyrazidol, inkazan and other antidepressant monoamine oxidase inhibitors on the pressor effect of tyramine. Farmakol. Toksikol. 1991, 54(2):38-40.
6. Ask A.L., Fagervall I., Florvall L., Ross S.B., Ytterborn S. Selective inhibition of monoamine oxidase by p-aminosubstituted phenylalkylamines in catecholaminergic neurones. Neuropharmacology 1986, 25(1):33-40.
7. Avramovich-Tirosh Y., Bar-Am O., Amit T., Youdim M.B., Weinreb O. Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr. Alzheimer Res. 2010, 7(4):300-306.
8. Bach A.W.J., Lan N.C., Johnson D.L., Abell C.W., Bembenek M.E., Kwan S.-W., Seeburg P.H., Shih J.C. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:4934-4938.
9. Baghai T.C., Möller H.J., Rupprecht R. Recent progress in pharmacological and non-pharmacological treatment options of major depression. Curr. Pharm. Des. 2006, 12(4):503-515.
10. Bar-Am O., Amit T., Kupershmidt L., Aluf Y., Mechlovich D., Kabha H., Danovitch L., Zurawski V.R., Youdim M.B., Weinreb O. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging. Neurobiol. Aging 2015, 36(3):1529-1542.
11. Bayer T.A., Wirths O. Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease. Acta Neuropathol. 2014, 127(6):787-801.
12. Bedrosian T.A., Nelson R.J. Nitric oxide and serotonin interactions in aggression. Curr. Top. Behav. Neurosci. 2014, 17:131-142.
13. Belmaker R.H., Agam G. Major depressive disorder. N. Engl. J. Med. 2008, 358(1):55-68.
14. Benek O., Soukup O., Pasdiorova M., Hroch L., Sepsova V., Jost P., Hrabinova M., Jun D., Kuca K., Zala D., Ramsay R.R., Marco-Contelles J., Musilek K. Design, synthesis and in vitro evaluation of indolotacrine analogues as multitarget-directed ligands for the treatment of Alzheimer's disease. ChemMedChem 2015, (Oct 2 2015). 10.1002/cmdc.201500383.
15. Berk M., Dodd S., Kauer-Sant'anna M., Malhi G.S., Bourin M., Kapczinski F., Norman T. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. SUPPL.. 2007, 434:41-49.
16. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., Yücel M., Gama C.S., Dodd S., Dean B., Magalhães P.V., Amminger P., McGorry P., Malhi G.S. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 2011, 35(3):804-817.
17. Berlin I., Zimmer R., Thiede H.M., Payan C., Hergueta T., Robin L., Puech A.J. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br. J. Clin. Pharmacol. 1990, 30(6):805-816.
18. Binda C., Mattevi A., Edmondson D.E. Structural properties of human monoamine oxidases A and B. Int. Rev. Neurobiol. 2011, 100:1-11.
19. Blanco C., Schneier F.R., Schmidt A., Blanco-Jerez C.R., Marshall R.D., Sánchez-Lacay A., Liebowitz M.R. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress. Anxiety 2003, 18(1):29-40.
20. Bolea I., Juárez-Jiménez J., de Los Ríos C., Chioua M., Pouplana R., Luque F.J., Unzeta M., Marco-Contelles J., Samadi A. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem. 2011, 54(24):8251-8270.
21. Bolea I., Gella A., Unzeta M. Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors. J. Neural Transm. 2013, 120(6):893-902.
22. Bolea I., Gella A., Monjas L., Pérez C., Rodríguez-Franco M.I., Marco-Contelles J., Samadi A., Unzeta M. Multipotent, permeable drug ASS234 inhibits Aβ aggregation, possesses antioxidant properties and protects from Aβ-induced apoptosis in vitro. Curr. Alzheimer Res. 2013, 10(8):797-808.
23. Bolognesi M.L., Cavalli A., Melchiorre C. Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics 2009, 6(1):152-162.
24. Bonda D.J., Wang X., Lee H.G., Smith M.A., Perry G., Zhu X. Neuronal failure in Alzheimer's disease: a view through the oxidative stress looking-glass. Neurosci. Bull. 2014, 30(2):243-252.
25. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003, 9(1):97-140.
26. Bortolato M., Chen K., Shih J.C. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv. Drug Deliv. Rev. 2008, 60(13-14):1527-1533.
27. Bortolato M., Godar S.C., Melis M., Soggiu A., Roncada P., Casu A., Flore G., Chen K., Frau R., Urbani A., Castelli M.P., Devoto P., Shih J.C. NMDARs mediate the role of monoamine oxidase A in pathological aggression. J. Neurosci. 2012, 32(25):8574-8582.
28. Boyer E.W., Shannon M. The serotonin syndrome. N. Engl. J. Med. 2005, 352(11):1112-1120.
29. Brown N.C., Andreazza A.C., Young L.T. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 2014, 218(1-2):61-68.
30. Brunner H.G., Nelen M., Breakefield X.O., Ropers H.H., van Oost B.A. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 1993, 262(5133):578-580.
31. Caccia C., Maj R., Calabresi M., Maestroni S., Faravelli L., Curatolo L., Salvati P., Fariello R.G. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006, 67(7 SUPPL. 2):S18-S23.
32. Cai Z. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (review). Mol. Med. Rep. 2014, 9(5):1533-1541.
33. Calabrese V., Cornelius C., Dinkova-Kostova A.T., Calabrese E.J., Mattson M.P. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid. Redox Signal. 2010, 13(11):1763-1811.
34. Cannon D.M., Carson R.E., Nugent A.C., Eckelman W.C., Kiesewetter D.O., Williams J., Rollis D., Drevets M., Gandhi S., Solorio G., Drevets W.C. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch. Gen. Psychiatry 2006, 63(7):741-747.
35. 2-receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol. Psychiatry 2011, 16(4):407-418.
36. Capurro V., Busquet P., Lopes J.P., Bertorelli R., Tarozzo G., Bolognesi M.L., Piomelli D., Reggiani A., Cavalli A. Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease. PLoS ONE 2013, 8(2).
37. Caspi A., McClay J., Moffitt T.E., Mill J., Martin J., Craig I.W., Taylor A., Poulton R. Role of genotype in the cycle of violence in maltreated children. Science 2002, 297(5582):851-854.
38. Chaturvedi R.K., Beal M.F. Mitochondrial diseases of the brain. Free Radic. Biol. Med. 2013, 63:1-29.
39. Chaudhury S., Sharma V., Kumar V., Nag T.C., Wadhwa S. Activity-dependent synaptic plasticity modulates the critical phase of brain development. Brain Dev. 2016, 38(4):355-363.
40. Chen K., Ou X.M., Chen G., Choi S.H., Shih J.C. R1, a novel repressor of the human monoamine oxidase A. J. Biol. Chem. 2005, 280(12):11552-11559.
41. Chester D.S., DeWall C.N., Derefinko K.J., Estus S., Peters J.R., Lynam D.R., Jiang Y. Monoamine oxidase A (MAOA) genotype predicts greater aggression through impulsive reactivity to negative affect. Behav. Brain Res. 2015, 283:97-101.
42. Citri A., Malenka R.C. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 2008, 33(1):18-41.
43. Coppen A. The biochemistry of affective disorders. Br. J. Psychiatry 1967, 113(504):1237-1264.
44. Craddock N., Davé S., Greening J. Association studies of bipolar disorder. Bipolar Disord. 2001, 3(6):284-298.
45. Damier P., Kastner A., Agid Y., Hirsch E.C. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?. Neurology 1996, 46(5):1262-1269.
46. DeMaagd G., Philip A. Parkinson's disease and its management: part 3: nondopaminergic and nonpharmacological treatment options. P&T 2015, 40(10):668-679.
47. Devor E.J., Cloninger C.R., Hoffman P.L., Tabakoff B. Association of monoamine oxidase (MAO) activity with alcoholism and alcoholic subtypes. Am. J. Med. Genet. 1993, 48(4):209-213.
48. Di Marzo V., Matias I. Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 2005, 8:585-589.
49. Di Stefano A.F., Radicioni M.M., Rusca A. Pressor response to oral tyramine and monoamine oxidase inhibition during treatment with ralfinamide (NW-1029). Neurotox. Res. 2013, 23(4):315-326.
50. Dorfman H.M., Meyer-Lindenberg A., Buckholtz J.W. Neurobiological mechanisms for impulsive-aggression: the role of MAOA. Curr. Top. Behav. Neurosci. 2014, 17:297-313.
51. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997, 54:597-606.
52. Duman R.S. Synaptic plasticity and mood disorders. Mol. Psychiatry 2002, 7(SUPPL.. 1):S29-S34.
53. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59(12):1116-1127.
54. Duman R.S. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin. Neurosci. 2009, 11(3):239-255.
55. Duman R.S. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress. Anxiety 2014, 31(4):291-296.
56. Duncan J., Johnson S., Ou X.M. Monoamine oxidases in major depressive disorder and alcoholism. Drug Discov Ther. 2012, 6(3):112-122.
57. Duong A., Syed B., Scola G. Biomarkers for bipolar disorder: current insights. Curr. Biomark. Find. 2015, 5:79-92.
58. Edmondson D.E., Binda C., Wang J., Upadhyay A.K., Mattevi A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry 2009, 48:4220-4230.
59. Edmondson D.E. Hydrogen peroxide produced by mitochondrial monoamine oxidase catalysis: biological implications. Curr. Pharm. Des. 2014, 20(2):155-160.
60. Einat H., Manji H.K. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biol. Psychiatry 2006, 59(12):1160-1171.
61. Esteban G., Allan J., Samadi A., Mattevi A., Unzeta M., Marco-Contelles J., Binda C., Ramsay R.R. Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease. Biochim. Biophys. Acta 2014, 1844(6):1104-1110.
62. Fabbri C., Di Girolamo G., Serretti A. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2013, 162B(6):487-520.
63. Fagervall I., Ross S.B. Inhibition of monoamine oxidase in monoaminergic neurons in the rat brain by irreversible inhibitors. Biochem. Pharmacol. 1986, 35(8):1381-1387.
64. Fiedorowicz J.G., Swartz K.L. The role of monoamine oxidase inhibitors in current psychiatric practice. J. Psychiatr. Pract. 2004, 10(4):239-248.
65. Filic V., Vladic A., Stefulj J., Cicin-Sain L., Balija M., Sucic Z., Jernej B. Monoamine oxidases A and B gene polymorphisms in migraine patients. J. Neurol. Sci. 2005, 228(2):149-153.
66. Finberg J.P. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol. Ther. 2014, 143(2):133-152.
67. Fišar Z. Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedeberg's Arch. Pharmacol. 2010, 381(6):563-572.
68. Fišar Z., Hroudová J. Intracellular signalling pathways and mood disorders. Folia Biol. 2010, 56(4):135-148.
69. Fišar Z., Hroudová J., Raboch J. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinol. Lett. 2010, 31(5):645-656.
70. Fišar Z., Hroudová J., Korábečný J., Musílek K., Kuča K. In vitro effects of acetylcholinesterase reactivators on monoamine oxidase activity. Toxicol. Lett. 2011, 201(2):176-180.
71. Fišar Z. Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2012, 38(1):68-77.
72. Fišar Z., Hroudová J., Raboch J. Neurotransmission in mood disorders. Clinical, Research and Treatment Approaches to Affective Disorders 2012, 191-234. InTech, Rijeka, Croatia. M.F. Juruena (Ed.).
73. Fišar Z. Pathophysiology of mood disorders and mechanisms of action of antidepressants and mood stabilizers. Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders 2013, 103-134. New York, Springer. E.J. Van Bockstaele (Ed.).
74. Florvall L., Fagervall I., Ask A.L., Ross S.B. Selective monoamine oxidase inhibitors. 4. 4-aminophenethylamine derivatives with neuron-selective action. J. Med. Chem. 1986, 29(11):2250-2256.
75. Florvall L., Kumar Y., Ask A.L., Fagervall I., Rényi L., Ross S.B. Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. preparation and neuron-selective action of some 5-(2-aminoethyl)-2,3-dihydroindoles. J. Med. Chem. 1986, 29(8):1406-1412.
76. Fowler P.W., Balali-Mood K., Deol S., Coveney P.V., Sansom M.S. Monotopic enzymes and lipid bilayers: a comparative study. Biochemistry 2007, 46:3108-3115.
77. Francis P.T., Parsons C.G., Jones R.W. Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. Expert. Rev. Neurother. 2012, 12(11):1351-1365.
78. Fulton B., Benfield P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs 1996, 52(3):450-474.
79. Gallagher D.A., Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 2008, 22(7):563-586.
80. Gareri P., Falconi U., De Fazio P., De Sarro G. Conventional and new antidepressant drugs in the elderly. Prog. Neurobiol. 2000, 61(4):353-396.
81. Gerlach M., Maetzler W., Broich K., Hampel H., Rems L., Reum T., Riederer P., Stöffler A., Streffer J., Berg D. Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J. Neural Transm. 2012, 119(1):39-52.
82. 11C]-harmine binding to monoamine oxidase-A in the human brain. J. Cereb. Blood Flow Metab. 2006, 26(3):330-344.
83. Glover V., Sandler M., Owen F., Riley G.J. Dopamine is a monoamine oxidase B substrate in man. Nature 1977, 265(5589):80-81.
84. Goodman A. Neurobiology of addiction. An integrative review. Biochem. Pharmacol. 2008, 75:266-322.
85. Gould T.D., Dow E.R., O'Donnell K.C., Chen G., Manji H.K. Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway. CNS Neurol. Disord. Drug Targets 2007, 6(3):193-204.
86. Grover N.D., Limaye R.P., Gokhale D.V., Patil T.R. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease. Ind. J. Pharmacol. 2013, 45(6):547-555.
87. Grunewald M., Johnson S., Lu D., Wang Z., Lomberk G., Albert P.R., Stockmeier C.A., Meyer J.H., Urrutia R., Miczek K.A., Austin M.C., Wang J., Paul I.A., Woolverton W.L., Seo S., Sittman D.B., Ou X.M. Mechanistic role for a novel glucocorticoid-KLF11 (TIEG2) protein pathway in stress-induced monoamine oxidase A expression. J. Biol. Chem. 2012, 287(29):24195-24206.
88. Haefely W., Burkard W.P., Cesura A.M., Kettler R., Lorez H.P., Martin J.R., Richards J.G., Scherschlicht R., Da Prada M. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology 1992, 106(SUPPL.. 1):S6-S14.
89. Hasan F., McCrodden J.M., Kennedy N.P., Tipton K.F. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J. Neural Transm. SUPPL.. 1988, 26:1-9.
90. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984, 311(5985):467-469.
91. Heninger G.R., Delgado P.L., Charney D.S. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996, 29(1):2-11.
92. Henriot S., Kuhn C., Kettler R., Da Prada M. Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings. J. Neural Transm. SUPPL.. 1994, 41:321-325.
93. Heun R., Kockler M., Ptok U. Depression in Alzheimer's disease: is there a temporal relationship between the onset of depression and the onset of dementia?. Eur. Psychiatry 2002, 17(5):254-258.
94. Holt A., Berry M.D., Boulton A.A. On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neurotoxicology 2004, 25(1-2):251-266.
95. Horstink M., Tolosa E., Bonuccelli U., Deuschl G., Friedman A., Kanovsky P., Larsen J.P., Lees A., Oertel W., Poewe W., Rascol O. Sampaio C.; European Federation of Neurological Societies; Movement Disorder Society-European Section. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur. J. Neurol. 2006, 13:1170-1185.
96. Hroudová J., Singh N., Fišar Z. Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer's disease. Biomed. Res. Int. 2014, 2014:175062.
97. Huang L., Lu C., Sun Y., Mao F., Luo Z., Su T., Jiang H., Shan W., Li X. Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease. J. Med. Chem. 2012, 55(19):8483-8492.
98. Huang Y.Y., Cate S.P., Battistuzzi C., Oquendo M.A., Brent D., Mann J.J. An association between a functional polymorphism in the monoamine oxidase a gene promoter, impulsive traits and early abuse experiences. Neuropsychopharmacology 2004, 29(8):1498-1505.
99. Hubálek F., Binda C., Li M., Herzig Y., Sterling J., Youdim M.B., Mattevi A., Edmondson D.E. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J. Med. Chem. 2004, 47(7):1760-1766.
100. Hyman S.E., Malenka R.C., Nestler E.J. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu. Rev. Neurosci. 2006, 29:565-598.
101. Jakubauskiene E., Janaviciute V., Peciuliene I., Söderkvist P., Kanopka A. G/A polymorphism in intronic sequence affects the processing of MAO-B gene in patients with Parkinson disease. FEBS Lett. 2012, 586(20):3698-3704.
102. Jiang H., Jiang Q., Liu W., Feng J. Parkin suppresses the expression of monoamine oxidases. J. Biol. Chem. 2006, 281(13):8591-8599.
103. Jiang S., Xin R., Lin S., Qian Y., Tang G., Wang D., Wu X. Linkage studies between attention-deficit hyperactivity disorder and the monoamine oxidase genes. Am. J. Med. Genet. 2001, 105(8):783-788.
104. Kato T., Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2000, 2(3 Pt 1):180-190.
105. Kato T. Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs 2007, 21(1):1-11.
106. Kato T. Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium 2008, 44(1):92-102.
107. Kiray M., Bagriyanik H.A., Pekcetin C., Ergur B.U., Uysal N., Ozyurt D., Buldan Z. Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats. Physiol. Res. 2006, 55(2):205-212.
108. Kitani K., Minami C., Isobe K., Maehara K., Kanai S., Ivy G.O., Carrillo M.C. Why (-)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mech. Ageing Dev. 2002, 123(8):1087-1100.
109. Konradi C., Riederer P., Youdim M.B. Hydrogen peroxide enhances the activity of monoamine oxidase type-B but not of type-A: a pilot study. J. Neural Transm. SUPPL.. 1986, 22:61-73.
110. Lan N.C., Heinzmann C., Gal A., Klisak I., Orth U., Lai E., Grimsby J., Sparkes R.S., Mohandas T., Shih J.C. Human monoamine oxidase A and B genes map to Xp 11.23 and are deleted in a patient with Norrie disease. Genomics 1989, 4(4):552-559.
111. Lawrence K.R., Adra M., Gillman P.K. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin. Infect. Dis. 2006, 42(11):1578-1583.
112. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 2012, 36(2):764-785.
113. Lim Y.A., Grimm A., Giese M., Mensah-Nyagan A.G., Villafranca J.E., Ittner L.M., Eckert A., Götz J. Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol. PLoS ONE 2011, 6(12).
114. Linde K., Kriston L., Rücker G., Jamil S., Schumann I., Meissner K., Sigterman K., Schneider A. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann. Fam. Med. 2015, 13(1):69-79.
115. Lotufo-Neto F., Trivedi M., Thase M.E. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999, 20(3):226-247.
116. Lu C., Zhou Q., Yan J., Du Z., Huang L., Li X. A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 2013, 62:745-753.
117. Lühr S., Vilches-Herrera M., Fierro A., Ramsay R.R., Edmondson D.E., Reyes-Parada M., Cassels B.K., Iturriaga-Vásquez P. 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg. Med. Chem. 2010, 18(4):1388-1395.
118. Lyketsos C.G., Carrillo M.C., Ryan J.M., Khachaturian A.S., Trzepacz P., Amatniek J., Cedarbaum J., Brashear R., Miller D.S. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement. 2011, 7(5):532-539.
119. Macleod A.D., Counsell C.E., Ives N., Stowe R. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst. Rev. 2005, 3.
120. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., Kubera M., Bob P., Lerer B., Maj M. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 2009, 24(1):27-53.
121. Maes M., Kubera M., Obuchowiczwa E., Goehler L., Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol. Lett. 2011, 32(1):7-24.
122. Maes M., Fišar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20(3):127-150.
123. Mandel S., Weinreb O., Amit T., Youdim M.B. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res. Brain Res. Rev. 2005, 48(2):379-387.
124. Martinez A., Castro A. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin Investig. Drugs 2006, 15(1):1-12.
125. Maruyama W., Weinstock M., Youdim M.B., Nagai M., Naoi M. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci. Lett. 2003, 341(3):233-236.
126. Mattson M.P., Gleichmann M., Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008, 60(5):748-766.
127. McCormack P.L. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. CNS Drugs 2014, 28(11):1083-1097.
128. Merikangas K.R., Merikangas J.R. Combination monoamine oxidase inhibitor and beta-blocker treatment of migraine, with anxiety and depression. Biol. Psychiatry 1995, 38(9):603-610.
129. Mesulam M.M. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 1999, 24(3):521-529.
130. Meyer J.H., Ginovart N., Boovariwala A., Sagrati S., Hussey D., Garcia A., Young T., Praschak-Rieder N., Wilson A.A., Houle S. Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry 2006, 63(11):1209-1216.
131. Meyer J.H., Wilson A.A., Sagrati S., Miler L., Rusjan P., Bloomfield P.M., Clark M., Sacher J., Voineskos A.N., Houle S. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch. Gen. Psychiatry 2009, 66(12):1304-1312.
132. Meyer J.H. Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. Clin. Pharmacol. Ther. 2012, 91(2):201-214.
133. 1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiedeberg's Arch. Pharmacol. 2004, 369(5):516-524.
134. Moretti A., Caccia C., Calderini G., Menozzi M., Amico A. Studies on the mechanism of action of caroxazone, a new antidepressant drug. Biochem. Pharmacol. 1981, 30(19):2728-2731.
135. Morrison T.R., Melloni R.H. The role of serotonin, vasopressin, and serotonin/vasopressin interactions in aggressive behavior. Curr. Top. Behav. Neurosci. 2014, 17:189-228.
136. Nadanaciva S., Will Y. Current concepts in drug-induced mitochondrial toxicity. Curr. Protoc. Toxicol. 2009, (Chapter 2:Unit 2.15).
137. Nagatsu T., Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. J. Neural Transm. SUPPL.. 2006, 71:53-65.
138. Naoi M., Maruyama W., Youdim M.B., Yu P., Boulton A.A. Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase. Inflammopharmacology 2003, 11(2):175-181.
139. Naoi M., Maruyama W. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr. Pharm. Des. 2010, 16(25):2799-2817.
140. Naoi M., Maruyama W., Inaba-Hasegawa K. Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. Curr. Top. Med. Chem. 2012, 12(20):2177-2188.
141. Naoi M., Riederer P., Maruyama W. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. J. Neural Transm. 2016, 123(2):91-106.
142. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34(1):13-25.
143. Oldfield V., Keating G.M., Perry C.M. Rasagiline: a review of its use in the management of Parkinson's disease. Drugs 2007, 67(12):1725-1747.
144. Oreland L., Hallman J., Damberg M. Platelet MAO and personality-function and dysfunction. Curr. Med. Chem. 2004, 11(15):2007-2016.
145. Ou X.M., Chen K., Shih J.C. Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(29):10923-10928.
146. Ou X.M., Chen K., Shih J.C. Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J. Biol. Chem. 2006, 281(30):21512-21525.
147. Pacher P., Bátkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58:389-462.
148. Pavlov K.A., Chistiakov D.A., Chekhonin V.P. Genetic determinants of aggression and impulsivity in humans. J. Appl. Genet. 2012, 53(1):61-82.
149. Petzer A., Harvey B.H., Wegener G., Petzer J.P., Azure B. a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. Toxicol. Appl. Pharmacol. 2012, 258(3):403-409.
150. Pistacchi M., Martinello F., Gioulis M., Zambito Marsala S. Rasagiline and rapid symptomatic motor effect in Parkinson's disease: review of literature. Neurol Ther. 2013, 3(1):41-66.
151. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33(1):88-109.
152. Ramsay R.R., Gravestock M.B. Monoamine oxidases: to inhibit or not to inhibit. Mini Rev. Med. Chem. 2003, 3(2):129-136.
153. Ramsay R.R., Dunford C., Gillman P.K. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br. J. Pharmacol. 2007, 152(6):946-951.
154. Ramsay R.R., Olivieri A., Holt A. An improved approach to steady-state analysis of monoamine oxidases. J. Neural Transm. 2011, 118(7):1003-1019.
155. Rebola N., Srikumar B.N., Mulle C. Activity-dependent synaptic plasticity of NMDA receptors. J. Physiol. 2010, 588(Pt 1):93-99.
156. Reichardt L.F. Neurotrophin-regulated signalling pathways. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 2006, 361:1545-1564.
157. Riederer P., Danielczyk W., Grünblatt E. Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology 2004, 25:271-277.
158. Rivera M., Gutiérrez B., Molina E., Torres-González F., Bellón J.A., Moreno-Küstner B., King M., Nazareth I., Martínez-González L.J., Martínez-Espín E., Muñoz-García M.M., Motrico E., Martínez-Cañavate T., Lorente J.A., Luna J.D., Cervilla J.A. High-activity variants of the uMAOA polymorphism increase the risk for depression in a large primary care sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B(3):395-402.
159. Rogers J.T., Lahiri D.K. Metal and inflammatory targets for Alzheimer's disease. Curr. Drug Targets 2004, 5(6):535-551.
160. Rosell D.R., Siever L.J. The neurobiology of aggression and violence. CNS Spectr. 2015, 20(3):254-279.
161. Ross J.M., Olson L., Coppotelli G. Mitochondrial and ubiquitin proteasome system dysfunction in ageing and disease: two sides of the same coin?. Int. J. Mol. Sci. 2015, 16(8):19458-19476.
162. Samson J.A., Gurrera R.J., Nisenson L., Schildkraut J.J. Platelet monoamine oxidase activity and deficit syndrome schizophrenia. Psychiatry Res. 1995, 56(1):25-31.
163. Saura J., Bleuel Z., Ulrich J., Mendelowitsch A., Chen K., Shih J.C., Malherbe P., Da Prada M., Richards J.G. Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience 1996, 70(3):755-774.
164. Savitz J.B., Drevets W.C. Neuroreceptor imaging in depression. Neurobiol. Dis. 2013, 52:49-65.
165. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 1965, 122(5):509-522.
166. Schon E.A., DiMauro S., Hirano M., Gilkerson R.W. Therapeutic prospects for mitochondrial disease. Trends Mol. Med. 2010, 16(6):268-276.
167. Scola G., Andreazza A.C. Current state of biomarkers in bipolar disorder. Curr. Psychiatry Rep. 2014, 16(12):514.
168. Scola G., Andreazza A.C. The role of neurotrophins in bipolar disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2015, 56:122-128.
169. 11C] DASB. Psychopharmacology 2011, 213(2-3):555-562.
170. Serretti A., Mandelli L. The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future directions. Mol. Psychiatry 2008, 13(8):742-771.
171. Shi L., Yang Y., Li Z.L., Zhu Z.W., Liu C.H., Zhu H.L. Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg. Med. Chem. 2010, 18(4):1659-1664.
172. Shih J.C., Chen K., Ridd M.J. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 1999, 22:197-217.
173. Shih J.C., Wu J.B., Chen K. Transcriptional regulation and multiple functions of MAO genes. J. Neural Transm. 2011, 118(7):979-986.
174. Shoham S., Bejar C., Kovalev E., Schorer-Apelbaum D., Weinstock M. Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. Neuropharmacology 2007, 52(3):836-843.
175. Shulman K.I., Herrmann N., Walker S.E. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs 2013, 27(10):789-797.
176. Sieradzan K., Channon S., Ramponi C., Stern G.M., Lees A.J., Youdim M.B. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. J. Clin. Psychopharmacol. 1995, 15(4 SUPPL.. 2):51S-59S.
177. Siever L.J., Coursey R.D. Biological markers for schizophrenia and the biological high-risk approach. J. Nerv. Ment. dis. 1985, 173(1):4-16.
178. Song M.S., Matveychuk D., MacKenzie E.M., Duchcherer M., Mousseau D.D., Baker G.B. An update on amine oxidase inhibitors: multifaceted drugs. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 44:118-124.
179. Stahl S.M., Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008, 13:855-870.
180. Stahl S.M. Stahl's essential psychopharmacology. Neuroscientific Basis and Practical Applications 2013, Cambridge Univ Press, New York. fourth ed.
181. Sterling J., Herzig Y., Goren T., Finkelstein N., Lerner D., Goldenberg W., Miskolczi I., Molnar S., Rantal F., Tamas T., Toth G., Zagyva A., Zekany A., Finberg J., Lavian G., Gross A., Friedman R., Razin M., Huang W., Krais B., Chorev M., Youdim M.B., Weinstock M. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem. 2002, 45(24):5260-5279.
182. Stocchi F., Fossati C., Torti M. Rasagiline for the treatment of Parkinson's disease: an update. Expert. Opin. Pharmacother. 2015, 16(14):2231-2241.
183. Stork C., Renshaw P.F. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol. Psychiatry 2005, 10(10):900-919.
184. Strydom B., Malan S.F., Castagnoli N., Bergh J.J., Petzer J.P. Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg. Med. Chem. 2010, 18(3):1018-1028.
185. Sun Y., Zhang J., Yuan Y., Yu X., Shen Y., Xu Q. Study of a possible role of the monoamine oxidase A (MAOA) gene in paranoid schizophrenia among a Chinese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2012, 159B(1):104-111.
186. Tadic A., Rujescu D., Szegedi A., Giegling I., Singer P., Möller H.-J., Dahmen N. Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 117B(1):1-6.
187. Takahashi A., Miczek K.A. Neurogenetics of aggressive behavior: studies in rodents. Curr. Top. Behav. Neurosci. 2014, 17:3-44.
188. Takahashi M., Terwilliger R., Lane C., Mezes P.S., Conti M., Duman R.S. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J. Neurosci. 1999, 19(2):610-618.
189. Takehashi M., Tanaka S., Masliah E., Ueda K. Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant. Neurosci. Lett. 2002, 327(2):79-82.
190. Tan E.K., Khajavi M., Thornby J.I., Nagamitsu S., Jankovic J., Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000, 55(4):533-538.
191. Thome J., Sakai N., Shin K., Steffen C., Zhang Y.J., Impey S., Storm D., Duman R.S. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 2000, 20(11):4030-4036.
192. Tong J., Meyer J.H., Furukawa Y., Boileau I., Chang L.J., Wilson A.A., Houle S., Kish S.J. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J. Cereb. Blood Flow Metab. 2013, 33(6):863-871.
193. Tyrer P., Shawcross C. Monoamine oxidase inhibitors in anxiety disorders. J. Psychiatr. Res. 1988, 22(SUPPL.. 1):87-98.
194. Urwin R.E., Nunn K.P. Epistatic interaction between the monoamine oxidase A and serotonin transporter genes in anorexia nervosa. Eur. J. Hum. Genet. 2005, 13(3):370-375.
195. Valaasani K.R., Sun Q., Hu G., Li J., Du F., Guo Y., Carlson E.A., Gan X., Yan S.S. Identification of human ABAD inhibitors for rescuing Aβ-mediated mitochondrial dysfunction. Curr. Alzheimer Res. 2014, 11(2):128-136.
196. van Amsterdam J., Talhout R., Vleeming W., Opperhuizen A. Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction. Life Sci. 2006, 79(21):1969-1973.
197. Vanyukov M.M., Maher B.S., Devlin B., Tarter R.E., Kirillova G.P., Yu L.M., Ferrell R.E. Haplotypes of the monoamine oxidase genes and the risk for substance use disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 125B(1):120-125.
198. Wang L., Esteban G., Ojima M., Bautista-Aguilera O.M., Inokuchi T., Moraleda I., Iriepa I., Samadi A., Youdim M.B., Romero A., Soriano E., Herrero R., Fernández Fernández A.P., Martínez-Murillo Ricardo, Marco-Contelles J., Unzeta M. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem. 2014, 80:543-561.
199. Wargelius H.L., Malmberg K., Larsson J.O., Oreland L. Associations of MAOA-VNTR or 5HTT-LPR alleles with attention-deficit hyperactivity disorder symptoms are moderated by platelet monoamine oxidase B activity. Psychiatr. Genet. 2012, 22(1):42-45.
200. Weder N., Yang B.Z., Douglas-Palumberi H., Massey J., Krystal J.H., Gelernter J., Kaufman J. MAOA genotype, maltreatment, and aggressive behavior: the changing impact of genotype at varying levels of trauma. Biol. Psychiatry 2009, 65(5):417-424.
201. Weinreb O., Amit T., Bar-Am O., Youdim M.B. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann. N. Y. Acad. Sci. 2007, 1122:155-168.
202. Weinreb O., Bar-Am O., Amit T., Chillag-Talmor O., Youdim M.B. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 2004, 18(12):1471-1473.
203. Weinreb O., Drigues N., Sagi Y., Reznick A.Z., Amit T., Youdim M.B. The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection. Antioxid. Redox Signal. 2007, 9(2):169-179.
204. Weinreb O., Amit T., Bar-Am O., Youdim M.B. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in aging and Alzheimer's disease. Br. J. Pharmacol. 2015, (Aug 29 2015).
205. Weinstock M., Bejar C., Wang R.H., Poltyrev T., Gross A., Finberg J.P., Youdim M.B. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J. Neural Transm. SUPPL.. 2000, 60:157-169.
206. Weinstock M., Kirschbaum-Slager N., Lazarovici P., Bejar C., Youdim M.B., Shoham S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann. N. Y. Acad. Sci. 2001, 939:148-161.
207. Weinstock M., Poltyrev T., Bejar C., Youdim M.B. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology 2002, 160(3):318-324.
208. Weinstock M., Luques L., Poltyrev T., Bejar C., Shoham S. Ladostigil prevents age-related glial activation and spatial memory deficits in rats. Neurobiol. Aging 2011, 32(6):1069-1078.
209. Wu J.B., Chen K., Li Y., Lau Y.F., Shih J.C. Regulation of monoamine oxidase A by the SRY gene on the Y chromosome. FASEB J. 2009, 23(11):4029-4038.
210. Wu Y.H., Fischer D.F., Swaab D.F. A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer's disease patients. Brain Res. 2007, 1167:13-19.
211. Yan S.D., Fu J., Soto C., Chen X., Zhu H., Al-Mohanna F., Collison K., Zhu A., Stern E., Saido T., Tohyama M., Ogawa S., Roher A., Stern D. An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease. Nature 1997, 389(6652):689-695.
212. Yang S.Y., He X.Y., Isaacs C., Dobkin C., Miller D., Philipp M. Roles of 17β-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders. J. Steroid Biochem. Mol. Biol. 2014, 143:460-472.
213. Youdim M.B. Rasagiline: an anti-Parkinson drug with neuroprotective activity. Expert. Rev. Neurother. 2003, 3(6):737-749.
214. Youdim M.B., Fridkin M., Zheng H. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J. Neural Transm. 2004, 111(10-11):1455-1471.
215. Youdim M.B., Riederer P.F. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 2004, 63(7 SUPPL.. 2):S32-S35.
216. Youdim M.B., Bakhle Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br. J. Pharmacol. 2006, 147(SUPPL.. 1):S287-S296.
217. Youdim M.B., Edmondson D., Tipton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 2006, 7:295-309.
218. Youdim M.B.H., Oh Y.J. Promise of neurorestoration and mitochondrial biogenesis in Parkinson's disease with multi target drugs: an alternative to stem cell therapy. Exp. Neurobiol. 2013, 22(3):167-172.
219. Zarate C.A., Singh J., Manji H.K. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol. Psychiatry 2006, 59(11):1006-1020.
220. Zhang C.W., Hang L., Yao T.P., Lim K.L. Parkin regulation and neurodegenerative disorders. Front. Aging Neurosci. 2016, 7:248.
221. Zheng H., Amit T., Bar-Am O., Fridkin M., Youdim M.B., Mandel S.A. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. J. Alzheimers Dis. 2012, 30(1):1-16.